Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

Brett King; B. Ehst; Peter Foley; Pascal Reygagne; Manabu Ohyama; Jacek C Szepietowski; Zoran Popmihajlov; Francesco De Leonardis; Lauren Hippeli; Michelle Treitel; Bankole A. Johnson; Coryandar Gilvary; John Vaile; Carolin Daamen; Thierry Passeron

doi:10.1093/bjd/ljag109

March 21, 2026British Journal of Dermatology

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research investigates whether deucravacitinib effectively promotes hair regrowth in alopecia areata patients.
Conducted as a multicenter, randomized, double-blinded, placebo-controlled trial
Evaluated efficacy endpoints related to hair regrowth
Assessed safety profile relative to known outcomes for TYK2 inhibitor
Trial did not meet efficacy endpoints for hair regrowth
Deucravacitinib's safety profile aligns with previous data for TYK2 inhibitors

Implication

Phase II trial evaluates hair regrowth efficacy of deucravacitinib in alopecia areata, suggesting limited impact.

Abstract

This trial did not meet the efficacy endpoints and TYK2 inhibition by deucravacitinib may not play a major role in hair regrowth in patients with AA. The safety of deucravacitinib in patients with AA was consistent with the known safety profile of this TYK2 inhibitor.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

King et al. (2026) studied this question.

synapsesocial.com/papers/69ccb66716edfba7beb88107 https://doi.org/10.1093/bjd/ljag109

View at Publisher

Ask AI

Bookmark

Share

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from British Journal of Dermatology

Keep reading

More related papers

More from British Journal of Dermatology